Diagnosis and treatment of acromegaly complications

被引:0
作者
A. Giustina
F. F. Casanueva
F. Cavagnini
P. Chanson
D. Clemmons
L. A. Frohman
R. Gaillard
K. Ho
P. Jaquet
D. L. Kleinberg
S. W. J. Lamberts
G. Lombardi
M. Sheppard
C. J. Strasburger
M. L. Vance
J. A. H. Wass
S. Melmed
机构
[1] University of Brescia,Cedar
[2] Santiago de Compostela University,Sinai Research Institute
[3] University of Milan,undefined
[4] University of North Carolina,undefined
[5] University of Illinois,undefined
[6] University Hospital CHUV,undefined
[7] Garvan Institute of Medical Research,undefined
[8] Université de la Mediterraneé,undefined
[9] NY University Medical Center,undefined
[10] University Hospital,undefined
[11] School of Medicine,undefined
[12] University of Birmingham,undefined
[13] Charité Campus Mitte,undefined
[14] University of Virginia,undefined
[15] Radcliffe Infirmary,undefined
[16] UCLA School of Medicine,undefined
来源
Journal of Endocrinological Investigation | 2003年 / 26卷
关键词
Sleep Apnea; Octreotide; Pituitary Adenoma; Acromegaly; Carpal Tunnel Syndrome;
D O I
暂无
中图分类号
学科分类号
摘要
The Pituitary Society in conjunction with the European Neuroendocrine Association held a consensus workshop to develop guidelines for diagnosis and treatment of the co-morbid complications of acromegaly. Fifty nine pituitary specialists (endocrinologists, neurosurgeons and cardiologists) assessed the current published literature on acromegaly complications in light of recent advances in maintaining tight therapeutic control of GH hypersecretion. The impact of elevated GH levels on cardiovascular disease, hypertension, diabetes, sleep apnea, colon polyps, bone disease, reproductive disorders, and neuropsychologic complications were considered. Guidelines are proposed for effective management of these complications in the context of overall acromegaly control. When appropriate, requirements for prospective evidence-based studies and surveillance database development are enunciated. Effective management of co-morbid acromegaly complications will lead to improved morbidity and mortality in acromegaly.
引用
收藏
页码:1242 / 1247
页数:5
相关论文
共 127 条
  • [1] Giustina A(2000)Criteria for cure of acromegaly: a consensus statement J Clin Endocrinol Metab 85 526-9
  • [2] Barkan A(2002)Guidelines for Acromegaly Management J Clin Endocrinol Metab 87 4054-8
  • [3] Casanueva FF(1990)Acromegaly N Engl J Med 322 966-77
  • [4] Melmed S(2002)Long term effects of lanreotide SR and octreotide LAR on tumor shrinkage and GH hypersecretion in patients with previously untreated acromegaly Clin Endocrinol (Oxf) 56 65-71
  • [5] Casanueva FF(1998)Tight control of growth hormone: an attainable outcome for acromegaly treatment J Clin Endocrinol Metab 83 3409-10
  • [6] Cavagnini F(1998)Prevalence of hypertension in acromegalic patients: clinical measurement versus 24-hour ambulatory blood pressure monitoring Clin Endocrinol (Oxf) 48 140-52
  • [7] Melmed S(2000)Baseline and stimulated catecholamine secretion in normotensive patients with active acromegaly: acute effects of continous octreotide infusion Eur J Endocrinol 142 179-86
  • [8] Amato G(1990)Acromegaly and hypertension: prevalence and relationship to the renin-angiotensin aldosterone system Klin Wochenschr 68 583-7
  • [9] Mazziotti G(1998)Decreased regional blood flow in patients with acromegaly Clin Endocrinol (Oxf) 49 725-31
  • [10] Rotondi M(1995)Cardiopulmonary performance during exercise in acromegaly and the effects of acute suppression of growth hormone hypersecretion with octreotide Am J Cardiol 75 1042-7